CORVIA MEDICAL RELEASES TWO-YEAR CLINICAL TRIAL RESULTS CONFIRMING SUSTAINED BENEFIT AND SAFETY OF ITS ATRIAL SHUNT IN HEART FAILURE PATIENTS
(Adnkronos) – FIRST-EVER PHASE III RANDOMIZED CONTROLLED TRIAL OF ATRIAL SHUNT THERAPY SHOWS CONTINUED PROMISE TEWKSBURY, Mass., May 22, 2023 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment
